From one billionaire investor to another: NantPharm raises $125 million
This article was originally published in Scrip
Executive Summary
Blackstone, the New York-based investment firm with $190 billion under management, has put $125 million as a minority investor into the biologics and pharmaceutical manufacturing unit of Nantworks - NantPharm - established in September 2011 by serial entrepreneur and billionaire philanthropist Patrick Soon-Shiong. The NantPharm unit is principally involved in pharmaceutical development and manufacturing.
You may also be interested in...
Celgene Settlement With Actavis Allows Abraxane Generics In 2022
Celgene settles Abraxane patent litigation and inter partes review with Teva's Actavis, allowing a generic to enter the market on March 31, 2022 – about four years before the drug's key patents expire.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.